Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Cell Line, Tumor"" wg kryterium: Temat


Tytuł:
miRNA profiling of human nasopharyngeal carcinoma cell lines HONE1 and CNE2 after X-ray therapy.
Autorzy:
Luo H; Department of Oncology, The First Affiliated Hospital of Nanchang University, China.
Zhong F; Department of Oncology, The First Affiliated Hospital of Nanchang University, China.
Jing X; Department of Oncology, Jiangxi Lushan People's Hospital, Jiujiang, China.
Lin H; Department of Oncology, The First Affiliated Hospital of Nanchang University, China.
Li Y; Department of Oncology, The First Affiliated Hospital of Nanchang University, China.
Pokaż więcej
Źródło:
Advances in clinical and experimental medicine : official organ Wroclaw Medical University [Adv Clin Exp Med] 2022 Jun; Vol. 31 (6), pp. 671-687.
Typ publikacji:
Journal Article
MeSH Terms:
Cell Line, Tumor*/metabolism
Cell Line, Tumor*/radiation effects
MicroRNAs*/genetics
MicroRNAs*/metabolism
Nasopharyngeal Carcinoma*/genetics
Nasopharyngeal Carcinoma*/radiotherapy
Nasopharyngeal Neoplasms*/genetics
Nasopharyngeal Neoplasms*/radiotherapy
Gene Expression Profiling ; Humans
Czasopismo naukowe
Tytuł:
Mutational signatures are markers of drug sensitivity of cancer cells.
Autorzy:
Levatić J; Genome Data Science, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, C/ Baldiri Reixac 10, 08028, Barcelona, Spain.
Salvadores M; Genome Data Science, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, C/ Baldiri Reixac 10, 08028, Barcelona, Spain.
Fuster-Tormo F; Genome Data Science, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, C/ Baldiri Reixac 10, 08028, Barcelona, Spain.; MDS Group, Josep Carreras Leukaemia Research Institute, Ctra de Can Ruti, Camí de les Escoles s/n, 08916, Badalona, Spain.
Supek F; Genome Data Science, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, C/ Baldiri Reixac 10, 08028, Barcelona, Spain. .; Catalan Institution for Research and Advanced Studies (ICREA), Passeig de Lluís Companys 23, 08010, Barcelona, Spain. .
Pokaż więcej
Źródło:
Nature communications [Nat Commun] 2022 May 25; Vol. 13 (1), pp. 2926. Date of Electronic Publication: 2022 May 25.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Cell Line, Tumor*/drug effects
Cell Line, Tumor*/metabolism
Drug Resistance, Neoplasm*/genetics
Exome*/genetics
Neoplasms*/drug therapy
Neoplasms*/genetics
DNA/metabolism ; DNA Mutational Analysis/methods ; Humans ; Mutation
Czasopismo naukowe
Tytuł:
Dual PI3Kδγ inhibition demonstrates potent anticancer effects in diffuse large B-cell lymphoma models: Discovery and preclinical characterization of LL-00084282.
Autorzy:
Verma MK; Novel Drug Discovery and Development, Lupin Limited, Lupin Research Park, Pune, Maharashtra, India, 412115. Electronic address: .
Samant C; Novel Drug Discovery and Development, Lupin Limited, Lupin Research Park, Pune, Maharashtra, India, 412115.
Kale R; Novel Drug Discovery and Development, Lupin Limited, Lupin Research Park, Pune, Maharashtra, India, 412115.
Patra S; Novel Drug Discovery and Development, Lupin Limited, Lupin Research Park, Pune, Maharashtra, India, 412115.
Mahajan N; Novel Drug Discovery and Development, Lupin Limited, Lupin Research Park, Pune, Maharashtra, India, 412115.
Gholve MK; Novel Drug Discovery and Development, Lupin Limited, Lupin Research Park, Pune, Maharashtra, India, 412115.
Marisetti A; Novel Drug Discovery and Development, Lupin Limited, Lupin Research Park, Pune, Maharashtra, India, 412115.
Sunkara B; Novel Drug Discovery and Development, Lupin Limited, Lupin Research Park, Pune, Maharashtra, India, 412115.
Naik A; Novel Drug Discovery and Development, Lupin Limited, Lupin Research Park, Pune, Maharashtra, India, 412115.
Shingare M; Novel Drug Discovery and Development, Lupin Limited, Lupin Research Park, Pune, Maharashtra, India, 412115.
Reddy M; Novel Drug Discovery and Development, Lupin Limited, Lupin Research Park, Pune, Maharashtra, India, 412115.
Bokare AM; Novel Drug Discovery and Development, Lupin Limited, Lupin Research Park, Pune, Maharashtra, India, 412115.
Akarte A; Novel Drug Discovery and Development, Lupin Limited, Lupin Research Park, Pune, Maharashtra, India, 412115.
Koul S; Novel Drug Discovery and Development, Lupin Limited, Lupin Research Park, Pune, Maharashtra, India, 412115.
Nigade PB; Novel Drug Discovery and Development, Lupin Limited, Lupin Research Park, Pune, Maharashtra, India, 412115.
Patil VB; Novel Drug Discovery and Development, Lupin Limited, Lupin Research Park, Pune, Maharashtra, India, 412115.
Modi D; Novel Drug Discovery and Development, Lupin Limited, Lupin Research Park, Pune, Maharashtra, India, 412115.
Ahirrao P; Novel Drug Discovery and Development, Lupin Limited, Lupin Research Park, Pune, Maharashtra, India, 412115.
Pawar S; Novel Drug Discovery and Development, Lupin Limited, Lupin Research Park, Pune, Maharashtra, India, 412115.
Kuldharan S; Novel Drug Discovery and Development, Lupin Limited, Lupin Research Park, Pune, Maharashtra, India, 412115.
Dinchhana L; Novel Drug Discovery and Development, Lupin Limited, Lupin Research Park, Pune, Maharashtra, India, 412115.
Mehta M; Novel Drug Discovery and Development, Lupin Limited, Lupin Research Park, Pune, Maharashtra, India, 412115.
Gundu J; Novel Drug Discovery and Development, Lupin Limited, Lupin Research Park, Pune, Maharashtra, India, 412115.
Jana N; Novel Drug Discovery and Development, Lupin Limited, Lupin Research Park, Pune, Maharashtra, India, 412115.
Vidhate P; Novel Drug Discovery and Development, Lupin Limited, Lupin Research Park, Pune, Maharashtra, India, 412115.
Mahangare SJ; Novel Drug Discovery and Development, Lupin Limited, Lupin Research Park, Pune, Maharashtra, India, 412115.
Shukla MR; Novel Drug Discovery and Development, Lupin Limited, Lupin Research Park, Pune, Maharashtra, India, 412115.
Goel RN; Novel Drug Discovery and Development, Lupin Limited, Lupin Research Park, Pune, Maharashtra, India, 412115.
Bhonde M; Novel Drug Discovery and Development, Lupin Limited, Lupin Research Park, Pune, Maharashtra, India, 412115.
Kamboj RK; Novel Drug Discovery and Development, Lupin Limited, Lupin Research Park, Pune, Maharashtra, India, 412115.
Palle VP; Novel Drug Discovery and Development, Lupin Limited, Lupin Research Park, Pune, Maharashtra, India, 412115.
Pokaż więcej
Źródło:
Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2022 Dec 31; Vol. 637, pp. 267-275. Date of Electronic Publication: 2022 Nov 15.
Typ publikacji:
Journal Article
MeSH Terms:
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Lymphoma, Large B-Cell, Diffuse*/drug therapy
Phosphoinositide-3 Kinase Inhibitors*/pharmacology
Humans ; B-Lymphocytes ; Phosphatidylinositol 3-Kinases ; Cell Line, Tumor
Czasopismo naukowe
Tytuł:
LncRNA TM4SF19-AS1 exacerbates cell proliferation, migration, invasion, and EMT in head and neck squamous cell carcinoma via enhancing LAMC1 expression.
Autorzy:
Yu Z; Department of Otorhinolaryngology, First Hospital of Jilin University, Changchun, Jilin, China.
Wang X; Department of Otorhinolaryngology, First Hospital of Jilin University, Changchun, Jilin, China.
Niu K; Department of Otorhinolaryngology, First Hospital of Jilin University, Changchun, Jilin, China.
Sun L; Department of Otorhinolaryngology, First Hospital of Jilin University, Changchun, Jilin, China.
Li D; Department of Otorhinolaryngology, First Hospital of Jilin University, Changchun, Jilin, China.
Pokaż więcej
Źródło:
Cancer biology & therapy [Cancer Biol Ther] 2022 Dec 31; Vol. 23 (1), pp. 1-9.
Typ publikacji:
Journal Article
MeSH Terms:
Head and Neck Neoplasms*/genetics
MicroRNAs*/genetics
RNA, Long Noncoding*/genetics
RNA, Long Noncoding*/metabolism
Humans ; Cell Line, Tumor ; Cell Movement/genetics ; Cell Proliferation/genetics ; Epithelial-Mesenchymal Transition/genetics ; Gene Expression Regulation, Neoplastic ; Squamous Cell Carcinoma of Head and Neck/genetics
Czasopismo naukowe
Tytuł:
LncRNA DUXAP8 induces breast cancer radioresistance by modulating the PI3K/AKT/mTOR pathway and the EZH2-E-cadherin/RHOB pathway.
Autorzy:
Lei C; Department of General Surgery, the Fifth Hospital of Wuhan, Wuhan, China.
Li S; Department of Pharmacy, the Fifth Hospital of Wuhan, Wuhan, China.
Fan Y; Department of Cardiology, the Fifth Hospital of Wuhan, Wuhan, China.
Hua L; Department of Medical Examination Center, the Fifth Hospital of Wuhan, Wuhan, China.
Pan Q; Department of Blood Endocrinology, the Fifth Hospital of Wuhan, Wuhan, China.
Li Y; Department of General Surgery, the Fifth Hospital of Wuhan, Wuhan, China.
Long Z; Department of Oncology, the Fifth Hospital of Wuhan, Wuhan, China.
Yang R; Department of General Surgery, the Fifth Hospital of Wuhan, Wuhan, China.
Pokaż więcej
Źródło:
Cancer biology & therapy [Cancer Biol Ther] 2022 Dec 31; Vol. 23 (1), pp. 1-13.
Typ publikacji:
Journal Article
MeSH Terms:
RNA, Long Noncoding*/genetics
RNA, Long Noncoding*/metabolism
Breast Neoplasms*/genetics
Breast Neoplasms*/radiotherapy
Humans ; Female ; Proto-Oncogene Proteins c-akt/metabolism ; Phosphatidylinositol 3-Kinases/metabolism ; Signal Transduction ; Cell Line, Tumor ; Apoptosis ; TOR Serine-Threonine Kinases/metabolism ; Cadherins/genetics ; Cell Proliferation ; Enhancer of Zeste Homolog 2 Protein/genetics ; Enhancer of Zeste Homolog 2 Protein/metabolism
Czasopismo naukowe
Tytuł:
STEAP2 promotes osteosarcoma progression by inducing epithelial-mesenchymal transition via the PI3K/AKT/mTOR signaling pathway and is regulated by EFEMP2.
Autorzy:
Zhang D; Department of Orthopedics, Suzhou Hospital of Anhui Medical University, Suzhou, P.R. China.
Liu H; Department of Orthopedics, Xiangcheng No. 2 People's Hospital, Suzhou, P.R. China.
Wang W; Department of Orthopedics, Xiangcheng No. 2 People's Hospital, Suzhou, P.R. China.
Xu G; Department of Orthopedics, Xiangcheng No. 2 People's Hospital, Suzhou, P.R. China.
Yin C; Department of Orthopedics, Xiangcheng No. 2 People's Hospital, Suzhou, P.R. China.
Wang S; Department of Orthopedics, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Pokaż więcej
Źródło:
Cancer biology & therapy [Cancer Biol Ther] 2022 Dec 31; Vol. 23 (1), pp. 1-16.
Typ publikacji:
Journal Article
MeSH Terms:
Bone Neoplasms*/pathology
Epithelial-Mesenchymal Transition*/genetics
Osteosarcoma*/pathology
Oxidoreductases*/metabolism
Extracellular Matrix Proteins*/metabolism
Humans ; Cell Line, Tumor ; Cell Movement ; Cell Proliferation ; Phosphatidylinositol 3-Kinases/metabolism ; Proto-Oncogene Proteins c-akt/metabolism ; Signal Transduction ; TOR Serine-Threonine Kinases/metabolism
Czasopismo naukowe
Tytuł:
DDX24 regulates the chemosensitivity of hepatocellular carcinoma to sorafenib via mediating the expression of SNORA18.
Autorzy:
Gan H; Center for Interventional Medicine, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.; Guangdong Provincial Key Laboratory of Biomedical Imaging, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.; Guangdong Provincial Engineering Research Center of Molecular Imaging, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.
Li L; Center for Interventional Medicine, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.; Guangdong Provincial Key Laboratory of Biomedical Imaging, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.; Guangdong Provincial Engineering Research Center of Molecular Imaging, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.
Hu X; Center for Interventional Medicine, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.; Guangdong Provincial Key Laboratory of Biomedical Imaging, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.; Guangdong Provincial Engineering Research Center of Molecular Imaging, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.
Cai J; Center for Interventional Medicine, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.; Guangdong Provincial Key Laboratory of Biomedical Imaging, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.; Guangdong Provincial Engineering Research Center of Molecular Imaging, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.
Hu X; Center for Interventional Medicine, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.
Zhang H; Center for Interventional Medicine, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.; Guangdong Provincial Key Laboratory of Biomedical Imaging, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.; Guangdong Provincial Engineering Research Center of Molecular Imaging, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.
Zhao N; Center for Interventional Medicine, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.
Xu X; The Cancer Center of the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong Province, China.
Guo H; Center for Interventional Medicine, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.
Pang P; Center for Interventional Medicine, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.; Guangdong Provincial Key Laboratory of Biomedical Imaging, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.; Guangdong Provincial Engineering Research Center of Molecular Imaging, the Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, China.
Pokaż więcej
Źródło:
Cancer biology & therapy [Cancer Biol Ther] 2022 Dec 31; Vol. 23 (1), pp. 1-14.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/genetics
Carcinoma, Hepatocellular*/metabolism
Liver Neoplasms*/drug therapy
Liver Neoplasms*/genetics
Liver Neoplasms*/metabolism
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Humans ; Sorafenib/pharmacology ; Sorafenib/therapeutic use ; Cell Line, Tumor ; Apoptosis ; Cell Proliferation ; DEAD-box RNA Helicases/genetics ; DEAD-box RNA Helicases/pharmacology
Czasopismo naukowe
Tytuł:
Trojan horse treatment based on PEG-coated extracellular vesicles to deliver doxorubicin to melanoma in vitro and in vivo .
Autorzy:
Patras L; Department of Molecular Biology and Biotechnology, Center of Systems Biology, Biodiversity and Bioresources, Faculty of Biology and Geology, 'Babes-Bolyai' University, Cluj-Napoca, Romania.
Ionescu AE; Department of Enzymology, Institute of Biochemistry of the Romanian Academy, Bucharest, Romania.
Munteanu C; Department of Bioinformatics and Structural Biochemistry, Institute of Biochemistry of the Romanian Academy, Bucharest, Romania.
Hajdu R; Department of Molecular Biology and Biotechnology, Center of Systems Biology, Biodiversity and Bioresources, Faculty of Biology and Geology, 'Babes-Bolyai' University, Cluj-Napoca, Romania.
Kosa A; Department of Molecular Biology and Biotechnology, Center of Systems Biology, Biodiversity and Bioresources, Faculty of Biology and Geology, 'Babes-Bolyai' University, Cluj-Napoca, Romania.
Porfire A; Department of Pharmaceutical Technology and Biopharmacy, Faculty of Pharmacy, 'Iuliu Hatieganu' University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Licarete E; Department of Molecular Biology and Biotechnology, Center of Systems Biology, Biodiversity and Bioresources, Faculty of Biology and Geology, 'Babes-Bolyai' University, Cluj-Napoca, Romania.; Molecular Biology Centre, Interdisciplinary Research Institute in Bio-Nano-Sciences, 'Babes-Bolyai' University, Cluj-Napoca, Romania.
Rauca VF; Department of Molecular Biology and Biotechnology, Center of Systems Biology, Biodiversity and Bioresources, Faculty of Biology and Geology, 'Babes-Bolyai' University, Cluj-Napoca, Romania.
Sesarman A; Department of Molecular Biology and Biotechnology, Center of Systems Biology, Biodiversity and Bioresources, Faculty of Biology and Geology, 'Babes-Bolyai' University, Cluj-Napoca, Romania.
Luput L; Department of Molecular Biology and Biotechnology, Center of Systems Biology, Biodiversity and Bioresources, Faculty of Biology and Geology, 'Babes-Bolyai' University, Cluj-Napoca, Romania.
Bulzu P; Department of Molecular Biology and Biotechnology, Center of Systems Biology, Biodiversity and Bioresources, Faculty of Biology and Geology, 'Babes-Bolyai' University, Cluj-Napoca, Romania.
Chiroi P; Department of Molecular Biology and Biotechnology, Center of Systems Biology, Biodiversity and Bioresources, Faculty of Biology and Geology, 'Babes-Bolyai' University, Cluj-Napoca, Romania.
Tranca RA; Department of Molecular Biology and Biotechnology, Center of Systems Biology, Biodiversity and Bioresources, Faculty of Biology and Geology, 'Babes-Bolyai' University, Cluj-Napoca, Romania.
Meszaros MS; Department of Molecular Biology and Biotechnology, Center of Systems Biology, Biodiversity and Bioresources, Faculty of Biology and Geology, 'Babes-Bolyai' University, Cluj-Napoca, Romania.
Negrea G; Department of Molecular Biology and Biotechnology, Center of Systems Biology, Biodiversity and Bioresources, Faculty of Biology and Geology, 'Babes-Bolyai' University, Cluj-Napoca, Romania.
Barbu-Tudoran L; 'C.Craciun' Electron Microscopy Center, Faculty of Biology and Geology, 'Babes-Bolyai' University, Cluj-Napoca, Romania.
Potara M; Nanobiophotonics Center, Interdisciplinary Research Institute in Bio-Nano-Sciences and Faculty of Physics, 'Babes-Bolyai' University, Cluj-Napoca, Romania.
Szedlacsek S; Department of Enzymology, Institute of Biochemistry of the Romanian Academy, Bucharest, Romania.
Banciu M; Department of Molecular Biology and Biotechnology, Center of Systems Biology, Biodiversity and Bioresources, Faculty of Biology and Geology, 'Babes-Bolyai' University, Cluj-Napoca, Romania.
Pokaż więcej
Źródło:
Cancer biology & therapy [Cancer Biol Ther] 2022 Dec 31; Vol. 23 (1), pp. 1-16. Date of Electronic Publication: 2021 Dec 29.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Extracellular Vesicles*
Melanoma, Experimental*/drug therapy
Melanoma, Experimental*/pathology
Animals ; Cell Line, Tumor ; Doxorubicin/pharmacology ; Doxorubicin/therapeutic use ; Humans ; Mice ; Polyethylene Glycols/therapeutic use
Czasopismo naukowe
Tytuł:
GANT61 suppresses cell survival, invasion and epithelial-mesenchymal transition through inactivating AKT/mTOR and JAK/STAT3 pathways in anaplastic thyroid carcinoma.
Autorzy:
Gao H; Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Wang W; Medical Department, RIGEN Biotechnology Co., Ltd, Shanghai, China.
Li Q; Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Pokaż więcej
Źródło:
Cancer biology & therapy [Cancer Biol Ther] 2022 Dec 31; Vol. 23 (1), pp. 369-377.
Typ publikacji:
Journal Article
MeSH Terms:
Thyroid Carcinoma, Anaplastic*/drug therapy
Thyroid Carcinoma, Anaplastic*/genetics
Thyroid Neoplasms*/pathology
Cell Line, Tumor ; Cell Movement ; Cell Survival ; Epithelial-Mesenchymal Transition/genetics ; Humans ; Phosphatidylinositol 3-Kinases/metabolism ; Proto-Oncogene Proteins c-akt/metabolism ; Pyridines ; Pyrimidines ; STAT3 Transcription Factor/metabolism ; TOR Serine-Threonine Kinases/metabolism
Czasopismo naukowe
Tytuł:
MiR-376a-3p increases cell apoptosis in acute myeloid leukemia by targeting MT1X.
Autorzy:
Xin X; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.; Department of Hematology, Xinyang Hospital Affiliated to Zhengzhou University, Xinyang, Henan, China.
Xu Z; Department of Hematology, Xinyang Hospital Affiliated to Zhengzhou University, Xinyang, Henan, China.
Wei J; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Zhang Y; Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Pokaż więcej
Źródło:
Cancer biology & therapy [Cancer Biol Ther] 2022 Dec 31; Vol. 23 (1), pp. 234-242.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Leukemia, Myeloid, Acute*/genetics
Leukemia, Myeloid, Acute*/metabolism
MicroRNAs*/genetics
MicroRNAs*/metabolism
3' Untranslated Regions ; Apoptosis/genetics ; Cell Line, Tumor ; Cell Proliferation/genetics ; Humans
Czasopismo naukowe
Tytuł:
Exosomal epidermal growth factor receptor is involved in HPV-16 E7-induced epithelial-mesenchymal transition of non-small cell lung cancer cells: A driver of signaling in vivo?
Autorzy:
Zhou Z; Institute of Biochemistry and Molecular Biology, Collaborative Innovation Center for antitumor active substance research and development, Guangdong Medical University, Zhanjiang, China.
Wu X; Institute of Biochemistry and Molecular Biology, Collaborative Innovation Center for antitumor active substance research and development, Guangdong Medical University, Zhanjiang, China.; Center for Laboratory Medicine, Department of Blood Transfusion, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Zhan R; Institute of Biochemistry and Molecular Biology, Collaborative Innovation Center for antitumor active substance research and development, Guangdong Medical University, Zhanjiang, China.; Center for Laboratory Medicine, Department of Blood Transfusion, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Li X; Institute of Biochemistry and Molecular Biology, Collaborative Innovation Center for antitumor active substance research and development, Guangdong Medical University, Zhanjiang, China.; Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, Dongguan Key Laboratory of Medical Bioactive Molecular Developmental and Translational Research, Guangdong Medical University, Dongguan, China.
Cheng D; Institute of Biochemistry and Molecular Biology, Collaborative Innovation Center for antitumor active substance research and development, Guangdong Medical University, Zhanjiang, China.
Chen L; Institute of Biochemistry and Molecular Biology, Collaborative Innovation Center for antitumor active substance research and development, Guangdong Medical University, Zhanjiang, China.
Wang T; Institute of Biochemistry and Molecular Biology, Collaborative Innovation Center for antitumor active substance research and development, Guangdong Medical University, Zhanjiang, China.
Yu H; Institute of Biochemistry and Molecular Biology, Collaborative Innovation Center for antitumor active substance research and development, Guangdong Medical University, Zhanjiang, China.
Zhang G; Institute of Biochemistry and Molecular Biology, Collaborative Innovation Center for antitumor active substance research and development, Guangdong Medical University, Zhanjiang, China.
Tang X; Institute of Biochemistry and Molecular Biology, Collaborative Innovation Center for antitumor active substance research and development, Guangdong Medical University, Zhanjiang, China.; Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, Dongguan Key Laboratory of Medical Bioactive Molecular Developmental and Translational Research, Guangdong Medical University, Dongguan, China.
Pokaż więcej
Źródło:
Cancer biology & therapy [Cancer Biol Ther] 2022 Dec 31; Vol. 23 (1), pp. 1-13.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/metabolism
Exosomes*/metabolism
Lung Neoplasms*/genetics
Lung Neoplasms*/metabolism
MicroRNAs*/genetics
Papillomavirus Infections*/complications
Cell Line, Tumor ; Epithelial-Mesenchymal Transition/genetics ; ErbB Receptors/genetics ; Human papillomavirus 16 ; Humans ; Papillomavirus E7 Proteins/genetics ; Papillomavirus E7 Proteins/metabolism
Czasopismo naukowe
Tytuł:
Targeting mitochondrial tyrosyl-tRNA synthetase YARS2 suppresses colorectal cancer progression.
Autorzy:
Fang Q; Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou 310014, China.
Lin J; Heart Center, Department of Cardiovascular Medicine, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou 310014, China.
Gao L; Cancer Center, Department of Medical Oncology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou 310014, China.
Pan R; Key Laboratory of Cell-Based Drug and Applied Technology Development in Zhejiang Province, Institute for Cell-Based Drug Development of Zhejiang Province, Hangzhou, China.
Zheng X; Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou 310014, China.
Pokaż więcej
Źródło:
Cancer biology & therapy [Cancer Biol Ther] 2022 Dec 31; Vol. 23 (1), pp. 1-8.
Typ publikacji:
Journal Article
MeSH Terms:
Colorectal Neoplasms*/drug therapy
Colorectal Neoplasms*/genetics
Tyrosine-tRNA Ligase*/genetics
Tyrosine-tRNA Ligase*/metabolism
Adenosine Triphosphate ; Cell Line, Tumor ; Fluorouracil ; Humans ; Mutation ; RNA, Messenger ; RNA, Transfer, Tyr ; Reactive Oxygen Species
Czasopismo naukowe
Tytuł:
CRC-derived exosomes containing the RNA binding protein HuR promote lung cell proliferation by stabilizing c-Myc mRNA.
Autorzy:
Xiao H; Department of Respiratory and Critical Care Medicine, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China.; Department of Molecular Biosciences, University of Kansas Cancer Center, University of Kansas, Lawrence, Kansas, USA.
Ye X; College of Clinical Medicine, Shanghai University of Medicine & Health Science, Shanghai, China.
Vishwakarma V; Department of Molecular Biosciences, University of Kansas Cancer Center, University of Kansas, Lawrence, Kansas, USA.
Preet R; Department of Molecular Biosciences, University of Kansas Cancer Center, University of Kansas, Lawrence, Kansas, USA.
Dixon DA; Department of Molecular Biosciences, University of Kansas Cancer Center, University of Kansas, Lawrence, Kansas, USA.
Pokaż więcej
Źródło:
Cancer biology & therapy [Cancer Biol Ther] 2022 Dec 31; Vol. 23 (1), pp. 139-149.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Colonic Neoplasms*/genetics
Colonic Neoplasms*/metabolism
Colonic Neoplasms*/pathology
ELAV-Like Protein 1*/genetics
Exosomes*/genetics
Exosomes*/metabolism
Lung Neoplasms*/genetics
Lung Neoplasms*/metabolism
MicroRNAs*/genetics
MicroRNAs*/metabolism
Proto-Oncogene Proteins c-myc*/genetics
Proto-Oncogene Proteins c-myc*/metabolism
RNA, Messenger*/genetics
RNA, Messenger*/metabolism
Cell Line, Tumor ; Cell Proliferation ; HCT116 Cells ; Humans ; Lung/pathology ; RNA-Binding Proteins/metabolism
Czasopismo naukowe
Tytuł:
Repeated treatments of Capan-1 cells with PARP1 and Chk1 inhibitors promote drug resistance, migration and invasion.
Autorzy:
Guo N; Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.; University of Chinese Academy of Sciences, Beijing, China.
Li MZ; Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.; University of Chinese Academy of Sciences, Beijing, China.
Wang LM; Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.; University of Chinese Academy of Sciences, Beijing, China.
Chen HD; Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.; University of Chinese Academy of Sciences, Beijing, China.
Song SS; Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Miao ZH; Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.; University of Chinese Academy of Sciences, Beijing, China.
He JX; Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.; University of Chinese Academy of Sciences, Beijing, China.
Pokaż więcej
Źródło:
Cancer biology & therapy [Cancer Biol Ther] 2022 Dec 31; Vol. 23 (1), pp. 69-82. Date of Electronic Publication: 2022 Jan 09.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Apoptosis*
Poly(ADP-ribose) Polymerase Inhibitors*/pharmacology
Poly(ADP-ribose) Polymerase Inhibitors*/therapeutic use
Cell Line, Tumor ; Drug Resistance ; G2 Phase Cell Cycle Checkpoints ; Humans ; Phthalazines/pharmacology ; Poly (ADP-Ribose) Polymerase-1/genetics ; Protein Kinase Inhibitors/pharmacology
Czasopismo naukowe
Tytuł:
PSMD12 promotes the activation of the MEK-ERK pathway by upregulating KIF15 to promote the malignant progression of liver cancer.
Autorzy:
Zhang H; Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, P. R. China.; Department of Colorectal Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Li C; Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, P. R. China.
Liao S; Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, P. R. China.
Tu Y; Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, P. R. China.
Sun S; Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, P. R. China.
Yao F; Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, P. R. China.
Li Z; Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, P. R. China.
Wang Z; Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan, P. R. China.
Pokaż więcej
Źródło:
Cancer biology & therapy [Cancer Biol Ther] 2022 Dec 31; Vol. 23 (1), pp. 1-11.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/pathology
Cell Line, Tumor ; Cell Proliferation ; Gene Expression Regulation, Neoplastic ; Humans ; Kinesins/genetics ; MAP Kinase Signaling System ; Neoplasm Recurrence, Local ; Proteasome Endopeptidase Complex/metabolism ; Sincalide/metabolism
Czasopismo naukowe
Tytuł:
SOX2 inhibits LLGL2 polarity protein in esophageal squamous cell carcinoma via miRNA-142-3p.
Autorzy:
Zhang S; Central Laboratory, Xiang'an Hospital of Xiamen University, Xiamen, China.; Centre for Regenerative Medicine, Institute for Regeneration and Repair, The University of Edinburgh, Edinburgh, UK.
Chen Y; Central Laboratory, Xiang'an Hospital of Xiamen University, Xiamen, China.; School of Medicine, Xiamen University, Xiamen, China.
Hu Q; School of Medicine, Xiamen University, Xiamen, China.; Department of Clinic Medical Laboratory, Zhoushan Hospital, Zhoushan, China.
Zhao T; Central Laboratory, Xiang'an Hospital of Xiamen University, Xiamen, China.; School of Medicine, Xiamen University, Xiamen, China.
Wang Z; Central Laboratory, Xiang'an Hospital of Xiamen University, Xiamen, China.; School of Medicine, Xiamen University, Xiamen, China.
Zhou Y; Central Laboratory, Xiang'an Hospital of Xiamen University, Xiamen, China.; School of Medicine, Xiamen University, Xiamen, China.
Wei Y; Central Laboratory, Xiang'an Hospital of Xiamen University, Xiamen, China.; School of Medicine, Xiamen University, Xiamen, China.
Zhao H; Central Laboratory, Xiang'an Hospital of Xiamen University, Xiamen, China.; School of Medicine, Xiamen University, Xiamen, China.
Wang J; School of Life Sciences, Xiamen University, Xiamen, China.
Yang Y; Department of Biology, University of Rochester, Rochester, New York, USA.
Zhang J; School of Life Sciences, Xiamen University, Xiamen, China.
Shi S; School of Medicine, Xiamen University, Xiamen, China.
Zhang Y; School of Medicine, Xiamen University, Xiamen, China.
Yang L; School of Medicine, Xiamen University, Xiamen, China.
Fu Z; Department of radiotherapy, 900 Hospital of the Joint Logistics Team (Dongfang Hospital, Xiamen University), Fuzhou, China.
Liu K; Central Laboratory, Xiang'an Hospital of Xiamen University, Xiamen, China.; School of Medicine, Xiamen University, Xiamen, China.
Pokaż więcej
Źródło:
Cancer biology & therapy [Cancer Biol Ther] 2022 Dec 31; Vol. 23 (1), pp. 1-15.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Squamous Cell*/pathology
Esophageal Neoplasms*/pathology
Esophageal Squamous Cell Carcinoma*/genetics
Esophageal Squamous Cell Carcinoma*/pathology
MicroRNAs*/genetics
MicroRNAs*/metabolism
Cell Line, Tumor ; Cell Movement ; Cell Proliferation ; Gene Expression Regulation, Neoplastic ; Humans ; SOXB1 Transcription Factors/genetics ; SOXB1 Transcription Factors/metabolism ; Sincalide/metabolism
Czasopismo naukowe
Tytuł:
Targeting long non-coding RNA PVT1/TGF-β/Smad by p53 prevents glioma progression.
Autorzy:
Li Z; Department of Clinical Laboratory, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan,Shandong Province, China.
Li M; Department of Clinical Laboratory, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan,Shandong Province, China.
Xia P; Department of Clinical Laboratory, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan,Shandong Province, China.
Wang L; Department of Clinical Laboratory, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan,Shandong Province, China.
Lu Z; Department of Clinical Laboratory, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan,Shandong Province, China.
Pokaż więcej
Źródło:
Cancer biology & therapy [Cancer Biol Ther] 2022 Dec 31; Vol. 23 (1), pp. 225-233.
Typ publikacji:
Journal Article
MeSH Terms:
Glioma*/pathology
MicroRNAs*/genetics
RNA, Long Noncoding*/genetics
RNA, Long Noncoding*/metabolism
Animals ; Cell Line, Tumor ; Cell Movement/genetics ; Cell Proliferation/genetics ; Gene Expression Regulation, Neoplastic ; Humans ; Mice ; RNA, Small Interfering ; Transforming Growth Factor beta ; Tumor Suppressor Protein p53/genetics ; Tumor Suppressor Protein p53/metabolism
Czasopismo naukowe
Tytuł:
Graphene quantum dots mediated magnetic chitosan drug delivery nanosystems for targeting synergistic photothermal-chemotherapy of hepatocellular carcinoma.
Autorzy:
Chen L; Department of Orthopedics, Chun'an First People's Hospital, Zhejiang Provincial People's Hospital Chun'an Branch, Hangzhou Medical College Affiliated Chun'an Hospital, Hangzhou, P.R. China.
Hong W; Clinical laboratory of Chun'an First People's Hospital, Zhejiang Provincial People's Hospital Chun'an Branch, Hangzhou Medical College Affiliated Chun'an Hospital, Hangzhou, P.R. China.
Duan S; The department of Immunology, Medical College, Guangxi University of Science and Technology, Liuzhou, P.R. China.
Li Y; Clinical laboratory of Chun'an First People's Hospital, Zhejiang Provincial People's Hospital Chun'an Branch, Hangzhou Medical College Affiliated Chun'an Hospital, Hangzhou, P.R. China.
Wang J; Clinical laboratory of Chun'an First People's Hospital, Zhejiang Provincial People's Hospital Chun'an Branch, Hangzhou Medical College Affiliated Chun'an Hospital, Hangzhou, P.R. China.
Zhu J; Clinical laboratory of Chun'an First People's Hospital, Zhejiang Provincial People's Hospital Chun'an Branch, Hangzhou Medical College Affiliated Chun'an Hospital, Hangzhou, P.R. China.
Pokaż więcej
Źródło:
Cancer biology & therapy [Cancer Biol Ther] 2022 Dec 31; Vol. 23 (1), pp. 281-293.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Chitosan*/therapeutic use
Graphite*/therapeutic use
Liver Neoplasms*/drug therapy
Nanoparticles*
Quantum Dots*
Animals ; Cell Line, Tumor ; Doxorubicin/pharmacology ; Drug Delivery Systems/methods ; Humans ; Magnetic Phenomena ; Mice
Czasopismo naukowe
Tytuł:
Crosstalk between PI3K/Akt and Wnt/β-catenin pathways promote colorectal cancer progression regardless of mutational status.
Autorzy:
Fleming-de-Moraes CD; Cellular and Molecular Oncobiology Program, Cellular Dynamic and Structure Group, Instituto Nacional de Cancer - INCA, Rio de Janeiro, Brazil.
Rocha MR; Cellular and Molecular Oncobiology Program, Cellular Dynamic and Structure Group, Instituto Nacional de Cancer - INCA, Rio de Janeiro, Brazil.
Tessmann JW; Cellular and Molecular Oncobiology Program, Cellular Dynamic and Structure Group, Instituto Nacional de Cancer - INCA, Rio de Janeiro, Brazil.
de Araujo WM; Cellular and Molecular Oncobiology Program, Cellular Dynamic and Structure Group, Instituto Nacional de Cancer - INCA, Rio de Janeiro, Brazil.; Institute of Biological and Health Sciences, Federal Rural University of Rio de Janeiro, Rio de Janeiro, Brazil.
Morgado-Diaz JA; Cellular and Molecular Oncobiology Program, Cellular Dynamic and Structure Group, Instituto Nacional de Cancer - INCA, Rio de Janeiro, Brazil.
Pokaż więcej
Źródło:
Cancer biology & therapy [Cancer Biol Ther] 2022 Dec 31; Vol. 23 (1), pp. 1-13.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Colorectal Neoplasms*/pathology
beta Catenin*/genetics
beta Catenin*/metabolism
Cell Line, Tumor ; Cell Proliferation ; Humans ; Insulin-Like Growth Factor I/genetics ; Insulin-Like Growth Factor I/pharmacology ; Mutation ; Phosphatidylinositol 3-Kinases/metabolism ; Phosphoinositide-3 Kinase Inhibitors ; Proto-Oncogene Proteins c-akt/metabolism ; Wnt Signaling Pathway/genetics
Czasopismo naukowe
Tytuł:
BRD4 PROTAC degrader MZ1 exerts anticancer effects in acute myeloid leukemia by targeting c-Myc and ANP32B genes.
Autorzy:
Ma L; Department of Hematology, Children's Hospital of Soochow University, Suzhou, China.; Department of Pediatrics, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huaian, China.
Wang J; Institute of Pediatric Research, Children's Hospital of Soochow University, Suzhou, China.
Zhang Y; Department of Hematology, Children's Hospital of Soochow University, Suzhou, China.
Fang F; Institute of Pediatric Research, Children's Hospital of Soochow University, Suzhou, China.
Ling J; Department of Hematology, Children's Hospital of Soochow University, Suzhou, China.
Chu X; Department of Hematology, Children's Hospital of Soochow University, Suzhou, China.
Zhang Z; Institute of Pediatric Research, Children's Hospital of Soochow University, Suzhou, China.
Tao Y; Institute of Pediatric Research, Children's Hospital of Soochow University, Suzhou, China.
Li X; Institute of Pediatric Research, Children's Hospital of Soochow University, Suzhou, China.
Tian Y; Department of Hematology, Children's Hospital of Soochow University, Suzhou, China.; Institute of Pediatric Research, Children's Hospital of Soochow University, Suzhou, China.
Li Z; Department of Hematology, Children's Hospital of Soochow University, Suzhou, China.
Sang X; Department of Hematology, Children's Hospital of Soochow University, Suzhou, China.
Zhang K; Department of Hematology, Children's Hospital of Soochow University, Suzhou, China.
Lu L; Department of Hematology, Children's Hospital of Soochow University, Suzhou, China.
Wan X; Department of Hematology, Children's Hospital of Soochow University, Suzhou, China.
Chen Y; Department of Hematology, Children's Hospital of Soochow University, Suzhou, China.
Yu J; Department of Hematology, Children's Hospital of Soochow University, Suzhou, China.
Zhuo R; Department of Hematology, Children's Hospital of Soochow University, Suzhou, China.
Wu S; Intensive Care Unit, Children's Hospital of Soochow University, Suzhou, China.
Lu J; Department of Hematology, Children's Hospital of Soochow University, Suzhou, China.
Pan J; Institute of Pediatric Research, Children's Hospital of Soochow University, Suzhou, China.
Hu S; Department of Hematology, Children's Hospital of Soochow University, Suzhou, China.
Pokaż więcej
Źródło:
Cancer biology & therapy [Cancer Biol Ther] 2022 Dec 31; Vol. 23 (1), pp. 1-15.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Dipeptides*/pharmacology
Heterocyclic Compounds, 3-Ring*/pharmacology
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Leukemia, Myeloid, Acute*/pathology
Animals ; Mice ; Apoptosis ; Cell Cycle Proteins/metabolism ; Cell Line, Tumor ; Nerve Tissue Proteins/metabolism ; Nuclear Proteins/metabolism ; Poly(ADP-ribose) Polymerase Inhibitors/pharmacology ; Proteolysis ; Proto-Oncogene Proteins c-myc/metabolism ; RNA ; Transcription Factors/metabolism
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies

Prześlij opinię

Twoje opinie są dla nas bardzo ważne i mogą być niezwykle pomocne w pokazaniu nam, gdzie możemy dokonać ulepszeń. Bylibyśmy bardzo wdzięczni za poświęcenie kilku chwil na wypełnienie krótkiego formularza.

Formularz